Theriva Biologics (TOVX) Stock Soars 63% on Promising Pancreatic Cancer Trial Results

Table of Contents During the American Association for Cancer Research (AACR) Annual Meeting held in San Diego on April 20, 2026, Theriva Biologics unveiled updated findings from its VIRAGE Phase 2b clinical study. Theriva Biologics, Inc., TOVX Dr. Manuel Hidalgo from NYU Langone Health’s Perlmutter Cancer Center presented the data during a poster session. The clinical investigation evaluated VCN-01 administered alongside gemcitabine and nab-paclitaxel versus standard chemotherapy alone in individuals recently diagnosed with metastatic pancreatic cancer. Findings revealed that participants who received the VCN-01 combination therapy experienced superior overall survival and progression-free survival metrics compared to the control group receiving only chemotherapy. The therapeutic responses observed in the VCN-01 treatment arm were characterized as emerging later in the treatment course, demonstrating greater magnitude, and exhibiting enhanced durability — suggesting what researchers believe represents an immune-mediated therapeutic mechanism. The survival advantages remained relatively consistent across diverse patient populations. This notably included individuals with liver metastases, a subgroup traditionally associated with more challenging treatment outcomes. Participants who were administered a second VCN-01 dose demonstrated potentially superior therapeutic benefits, which company officials interpret as supporting evidence for prolonged dosing strategies. Theriva Biologics announced it has successfully achieved regulatory alignment with both the U.S. Food and Drug Administration and the European Medicines Agency regarding the framework for a definitive Phase 3 clinical trial. The planned Phase 3 investigation would assess multiple VCN-01 dosing regimens combined with gemcitabine and nab-paclitaxel in treatment-naive metastatic pancreatic cancer patients. Additionally, the organization indicated intentions to conduct a supplementary investigation examining whether increased frequency or extended duration of VCN-01 administration could further enhance patient outcomes. VCN-01 represents a systemically delivered oncolytic adenovirus platform. The therapeutic agent is engineered to selectively replicate within malignant cells and degrade tumor stromal architecture, theoretically enhancing penetration and efficacy of concurrently administered treatments. To this point, the investigational therapy has been administered to 142 individuals across multiple clinical trials encompassing various malignancy types. TOVX shares experienced a 63% price increase following the announcement, though the organization maintains a relatively small market capitalization of merely $11.7 million with shares trading at $0.25. This valuation underscores the considerable risks inherent in investing in clinical-stage biotechnology companies without revenue generation and facing continued capital consumption. The latest analyst assessment on TOVX carries a Buy recommendation, establishing a price objective of $1.00. Analyst price targets span a range between $1 and $4. A notable complication: Theriva recently failed to convene a Special Meeting of Stockholders due to insufficient quorum attendance. The gathering was scheduled to vote on a warrant exercise proposition. Management intends to reconvene the meeting. Pancreatic ductal adenocarcinoma represents over 90% of all pancreatic malignancies, with approximately 50–60% of patients presenting with distant metastatic disease at initial diagnosis. The AACR data presentation occurred on April 20 between 2:00–5:00 PM PDT at the San Diego Convention Center.